Medifast (MED) Tops Q2 EPS by 64c; Lowers Outlook

Medifast (NYSE: MED) reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million.

GUIDANCE:

Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Pfizer lung cancer drug misses survival goal in Phase 3 trial